At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, and 3 other interventions for Adult Anaplastic Astrocytoma and 6 related conditions. Completed, enrolled 116 participants across 308 sites.
Detailed Summary
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with glioblastoma multiforme that has come back. Monoclonal antibodies, such as anti-endoglin monoclonal antibody TRC105 and bevacizumab, may find tumor cells and help kill them. Giving anti-endoglin monoclonal antibody TRC105 together with bevacizumab may be an effective treatment for glioblastoma multiforme.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies
Correlative studies
Ancillary studies